Annals of oncology, 2018-10, Vol.29 (10), p.2145-2147
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor
- Ist Teil von
- Annals of oncology, 2018-10, Vol.29 (10), p.2145-2147
- Ort / Verlag
- England: Elsevier Ltd
- Erscheinungsjahr
- 2018
- Quelle
- MEDLINE
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0923-7534eISSN: 1569-8041DOI: 10.1093/annonc/mdy312Titel-ID: cdi_crossref_primary_10_1093_annonc_mdy312
- Format
- –
- Schlagworte
- Antibodies, Monoclonal, Humanized - therapeutic use, Antineoplastic Agents, Immunological - therapeutic use, B7-H1 Antigen - metabolism, Carcinoma, Non-Small-Cell Lung - drug therapy, Carcinoma, Non-Small-Cell Lung - genetics, Carcinoma, Non-Small-Cell Lung - metabolism, Carcinoma, Non-Small-Cell Lung - pathology, ErbB Receptors - antagonists & inhibitors, ErbB Receptors - genetics, Erlotinib Hydrochloride - therapeutic use, Female, Humans, Lung Neoplasms - drug therapy, Lung Neoplasms - genetics, Lung Neoplasms - metabolism, Lung Neoplasms - pathology, Middle Aged, Mutation, Programmed Cell Death 1 Receptor - antagonists & inhibitors, Protein Kinase Inhibitors - therapeutic use, Treatment Outcome